JP2019522024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522024A5 JP2019522024A5 JP2019503999A JP2019503999A JP2019522024A5 JP 2019522024 A5 JP2019522024 A5 JP 2019522024A5 JP 2019503999 A JP2019503999 A JP 2019503999A JP 2019503999 A JP2019503999 A JP 2019503999A JP 2019522024 A5 JP2019522024 A5 JP 2019522024A5
- Authority
- JP
- Japan
- Prior art keywords
- transdermal delivery
- salt
- therapeutic agent
- drug reservoir
- delivery system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 72
- 230000037317 transdermal delivery Effects 0.000 claims description 45
- 229940124597 therapeutic agent Drugs 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 35
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 30
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 24
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 239000002585 base Substances 0.000 claims description 15
- 239000004821 Contact adhesive Substances 0.000 claims description 14
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 12
- 229960003530 donepezil Drugs 0.000 claims description 8
- 229960004640 memantine Drugs 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 208000017667 Chronic Disease Diseases 0.000 claims description 7
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 7
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 claims description 7
- 239000001069 triethyl citrate Substances 0.000 claims description 7
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 7
- 235000013769 triethyl citrate Nutrition 0.000 claims description 7
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 6
- 150000001447 alkali salts Chemical class 0.000 claims description 6
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 5
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002367 Polyisobutene Polymers 0.000 claims description 4
- 229920000249 biocompatible polymer Polymers 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960003135 donepezil hydrochloride Drugs 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 2
- 229920005549 butyl rubber Polymers 0.000 claims description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 229960000967 memantine hydrochloride Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 229940055577 oleyl alcohol Drugs 0.000 claims description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- -1 polybutylene Polymers 0.000 claims description 2
- 229920001748 polybutylene Polymers 0.000 claims description 2
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 2
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 claims description 2
- 159000000011 group IA salts Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000007792 addition Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022025574A JP2022060428A (ja) | 2016-07-27 | 2022-02-22 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
| JP2024000683A JP2024019737A (ja) | 2016-07-27 | 2024-01-05 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367542P | 2016-07-27 | 2016-07-27 | |
| US201662367502P | 2016-07-27 | 2016-07-27 | |
| US62/367,542 | 2016-07-27 | ||
| US62/367,502 | 2016-07-27 | ||
| US201662423133P | 2016-11-16 | 2016-11-16 | |
| US62/423,133 | 2016-11-16 | ||
| US201762457794P | 2017-02-10 | 2017-02-10 | |
| US62/457,794 | 2017-02-10 | ||
| US201762504391P | 2017-05-10 | 2017-05-10 | |
| US201762504408P | 2017-05-10 | 2017-05-10 | |
| US62/504,408 | 2017-05-10 | ||
| US62/504,391 | 2017-05-10 | ||
| PCT/US2017/044047 WO2018022814A1 (en) | 2016-07-27 | 2017-07-26 | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025574A Division JP2022060428A (ja) | 2016-07-27 | 2022-02-22 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
| JP2024000683A Division JP2024019737A (ja) | 2016-07-27 | 2024-01-05 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019522024A JP2019522024A (ja) | 2019-08-08 |
| JP2019522024A5 true JP2019522024A5 (https=) | 2020-08-27 |
| JP7469879B2 JP7469879B2 (ja) | 2024-04-17 |
Family
ID=59593165
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503999A Active JP7469879B2 (ja) | 2016-07-27 | 2017-07-26 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
| JP2022025574A Pending JP2022060428A (ja) | 2016-07-27 | 2022-02-22 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
| JP2024000683A Pending JP2024019737A (ja) | 2016-07-27 | 2024-01-05 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025574A Pending JP2022060428A (ja) | 2016-07-27 | 2022-02-22 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
| JP2024000683A Pending JP2024019737A (ja) | 2016-07-27 | 2024-01-05 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20180028461A1 (https=) |
| EP (1) | EP3490559A1 (https=) |
| JP (3) | JP7469879B2 (https=) |
| KR (1) | KR102424270B1 (https=) |
| CN (1) | CN109789134A (https=) |
| AU (2) | AU2017302305A1 (https=) |
| CA (1) | CA3031944A1 (https=) |
| WO (1) | WO2018022814A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014031471B1 (pt) * | 2012-07-17 | 2020-12-01 | Dow Global Technologies Llc | composição líquida, uso da composição líquida, dispersão sólida, processo para produzir a dispersão sólida e processo para revestir uma forma de dosagem |
| US10966936B2 (en) | 2015-12-30 | 2021-04-06 | Corium, Inc. | Systems comprising a composite backing and methods for long term transdermal administration |
| WO2017223402A1 (en) | 2016-06-23 | 2017-12-28 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
| EP3490544A1 (en) | 2016-07-27 | 2019-06-05 | Corium International, Inc. | Memantine transdermal delivery systems |
| CN116270551A (zh) | 2016-07-27 | 2023-06-23 | 考里安有限责任公司 | 通过盐至中性药物原位转化的组合物、透皮贴剂及应用 |
| EP3558276B1 (en) | 2016-12-20 | 2024-11-06 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| CN115813888A (zh) | 2016-12-20 | 2023-03-21 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
| WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER |
| US11173132B2 (en) | 2017-12-20 | 2021-11-16 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| KR102372630B1 (ko) * | 2019-05-15 | 2022-03-14 | 주식회사 대웅제약 | 고함량의 도네페질 또는 그의 염을 포함하는 경피흡수제제 |
| WO2021003315A1 (en) * | 2019-07-02 | 2021-01-07 | Rowley Clifford T | Transdermal patch providing improved permeability |
| BR112022007369A2 (pt) * | 2019-10-24 | 2022-07-05 | Lts Lohmann Therapie Systeme Ag | Sistema terapêutico transdérmico para a administração transdérmica de fingolimode |
| CN112915071A (zh) * | 2019-11-20 | 2021-06-08 | 成都康弘药业集团股份有限公司 | 一种含有美金刚的透皮贴剂 |
| JP2025509831A (ja) * | 2022-03-14 | 2025-04-11 | エーアールエックス，エルエルシー | ある特定の第Ｘａ因子阻害剤のための経皮送達系並びに関連するそれらの調製方法及び使用 |
| KR20240146479A (ko) * | 2023-03-29 | 2024-10-08 | 아이큐어 주식회사 | 고용량 도네페질 약물탑재 지속방출 경피흡수제제 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| NL134681C (https=) | 1966-04-26 | |||
| US3546141A (en) | 1966-08-08 | 1970-12-08 | Mc Donnell Douglas Corp | Phosphorus-nitrogen polymers and process |
| ES413944A1 (es) | 1972-04-20 | 1976-06-01 | Merz & Co | Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5. |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| DE3572485D1 (en) | 1984-12-22 | 1989-09-28 | Thomae Gmbh Dr K | Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4781924A (en) | 1987-11-09 | 1988-11-01 | Alza Corporation | Transdermal drug delivery device |
| US4837027A (en) | 1987-11-09 | 1989-06-06 | Alza Corporation | Transdermal drug delivery device |
| US5026556A (en) | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
| ES2059602T3 (es) | 1989-04-14 | 1994-11-16 | Merz & Co Gmbh & Co | Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral. |
| US5252588A (en) | 1990-04-27 | 1993-10-12 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation |
| MX9100277A (es) | 1990-07-23 | 1992-02-28 | Alza Corp | Dispositivo osmotico oral para aplicar nicotina |
| US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5123900A (en) | 1991-08-16 | 1992-06-23 | Bertek, Inc. | Moisture permeable double disk |
| US5424077A (en) | 1993-07-13 | 1995-06-13 | Church & Dwight Co., Inc. | Co-micronized bicarbonate salt compositions |
| CA2198390C (en) | 1994-09-14 | 2009-08-11 | James E. Garbe | Matrix for transdermal drug delivery |
| WO1996040087A2 (en) | 1995-06-07 | 1996-12-19 | Cygnus, Inc. | Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group |
| DE19531342B4 (de) | 1995-08-25 | 2007-11-29 | Merz Pharma Gmbh & Co. Kgaa | Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren |
| US6929801B2 (en) | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| US5958919A (en) | 1996-09-20 | 1999-09-28 | Washington University | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration |
| CA2264687C (en) | 1996-10-24 | 2006-04-25 | Alza Corporation | Permeation enhancers for transdermal drug delivery compositions, devices, and methods |
| US5866585A (en) | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
| US6193993B1 (en) | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US20020192243A1 (en) * | 1999-12-16 | 2002-12-19 | Tsung-Min Hsu | Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers |
| US6455066B1 (en) | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
| US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| ES2331302T3 (es) | 2001-05-01 | 2009-12-29 | A.V. Topchiev Institute Of Petrochemical Synthesis | Composiciones de hidrogel. |
| WO2003015713A2 (en) | 2001-08-20 | 2003-02-27 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
| DK1423100T3 (da) | 2001-09-04 | 2007-05-29 | Trommsdorff Arzneimittel | Plaster indeholdende sertaconazol til behandling af negles dysfunktioner og lidelser |
| US7273619B2 (en) | 2002-01-17 | 2007-09-25 | Samyang Corporation | Transdermal composition of an antivomiting agent |
| TW200418446A (en) | 2002-10-24 | 2004-10-01 | Merz Pharma Gmbh & Co Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| ATE534373T1 (de) | 2003-10-10 | 2011-12-15 | Antares Pharma Ipl Ag | Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut |
| WO2005079779A1 (en) | 2003-10-22 | 2005-09-01 | Merz Pharma Gmbh & Co. Kgaa | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES |
| CA2546395A1 (en) | 2003-11-21 | 2005-06-09 | Memory Pharmaceutical Corporation | Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors |
| US7176185B2 (en) | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
| EP1715853A4 (en) | 2004-02-17 | 2012-07-18 | Transcept Pharmaceuticals Inc | COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF |
| US7670838B2 (en) | 2004-05-24 | 2010-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Coupling of excitation and neurogenesis in neural stem/progenitor cells |
| US20080038328A1 (en) | 2004-05-28 | 2008-02-14 | Naruhito Higo | Pasting Preparation |
| TW200616608A (en) | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| EP1807033B1 (en) | 2004-10-08 | 2016-07-20 | Noven Pharmaceuticals, Inc. | Transdermal drug delivery device including an occlusive backing |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| WO2006076562A1 (en) | 2005-01-11 | 2006-07-20 | Teva Pharmaceutical Fine Chemicals S.R.L. | Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride |
| ATE481096T1 (de) | 2005-04-06 | 2010-10-15 | Adamas Pharmaceuticals Inc | Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen |
| US7888422B2 (en) | 2005-11-09 | 2011-02-15 | Mylan Technologies Inc. | Long-wearing removable pressure sensitive adhesive |
| IL175338A0 (en) | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
| MY149152A (en) | 2006-05-08 | 2013-07-15 | Teikoku Seiyaku Kk | Percutaneous absorption preparations of antimentia drugs |
| JP5097359B2 (ja) * | 2006-05-09 | 2012-12-12 | 久光製薬株式会社 | ドネペジル経皮吸収型製剤 |
| US9248104B2 (en) | 2006-08-17 | 2016-02-02 | Core Tech Solutions, Inc. | Transdermal methods and systems for treating Alzheimer's disease |
| US20080107719A1 (en) | 2006-11-08 | 2008-05-08 | Sukhon Likitlersuang | Transdermal drug delivery system |
| RU2452474C2 (ru) * | 2006-12-01 | 2012-06-10 | Нитто Денко Корпорейшн | Стабилизированная адгезивная композиция, содержащая донепезил |
| EP2638906A1 (en) | 2006-12-01 | 2013-09-18 | Nitto Denko Corporation | Stabilized adhesive preparation containing donepezil |
| US20100062045A1 (en) | 2006-12-01 | 2010-03-11 | Nitto Denko Corporation | Method for suppressing coloring of adhesive prepartion containing donepezil and method for reducing amounts of donepezil-related substances formed |
| US8246978B2 (en) | 2007-07-10 | 2012-08-21 | Agile Therapeutics, Inc. | Dermal delivery device with reduced loss of its volatile components |
| DE102008013701A1 (de) * | 2008-03-11 | 2009-09-17 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System mit stabilisierter Membran |
| PE20100371A1 (es) | 2008-10-31 | 2010-06-01 | Lexicon Pharmaceuticals Inc | Agonistas del receptor s1p para el tratamiento de malaria cerebral |
| US20100178037A1 (en) | 2009-01-12 | 2010-07-15 | Te-Wei Chen | Display apparatus, video generation apparatus, and method thereof |
| WO2010083035A2 (en) | 2009-01-14 | 2010-07-22 | Corium International, Inc. | Transdermal administration of tamsulosin |
| JP5758290B2 (ja) | 2009-05-01 | 2015-08-05 | 久光製薬株式会社 | 経皮吸収型製剤 |
| BR112012011334A2 (pt) | 2009-10-21 | 2020-08-25 | Teikoku Seiyaku Co., Ltd. | formulação transdermicamente absorvível contendo donepezil |
| CN102048678A (zh) | 2009-10-30 | 2011-05-11 | 北京隆旗生物科技有限公司 | 一种奥昔布宁的透皮吸收制剂及其制备方法与药物应用 |
| GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
| JP2012236773A (ja) * | 2009-12-16 | 2012-12-06 | Goto Takeshi | 抗認知症薬物の経皮吸収製剤 |
| HUE025446T2 (en) | 2009-12-30 | 2016-04-28 | Novartis Ag | Melt extruded nicotine thin strips |
| US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| EP2564848B1 (en) * | 2010-04-28 | 2015-09-02 | Hisamitsu Pharmaceutical Co., Inc. | Transdermally absorbable donepezil-containing preparation |
| WO2011146583A2 (en) | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Nanoparticulate cinacalcet formulations |
| DE102010024105A1 (de) | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| US20140370076A1 (en) | 2010-06-30 | 2014-12-18 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing donepezil |
| JP5699554B2 (ja) | 2010-11-11 | 2015-04-15 | 富士通株式会社 | ベクトル処理回路、命令発行制御方法、及びプロセッサシステム |
| TWI433904B (zh) | 2011-01-12 | 2014-04-11 | Taiwan Biotech Co Ltd | 多奈哌齊經皮貼片 |
| US8673338B2 (en) | 2011-07-29 | 2014-03-18 | Massachusetts Eye And Ear Infirmary | Methods of delivering pharmaceutical agents |
| KR101239150B1 (ko) | 2012-02-28 | 2013-03-06 | 에스케이케미칼주식회사 | 도네페질-함유 경피흡수제제 및 그의 제조방법 |
| KR101948779B1 (ko) | 2013-10-07 | 2019-05-21 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법 |
| CN105611917A (zh) * | 2013-10-11 | 2016-05-25 | 帝国制药美国公司 | 局部鞘氨醇-1-磷酸酯受体激动剂制剂及其使用方法 |
| KR101485822B1 (ko) | 2014-01-22 | 2015-01-23 | 주식회사 대웅제약 | 도네페질 또는 그의 염을 함유하는 경피흡수제제 |
| CN107106510A (zh) | 2014-12-18 | 2017-08-29 | Icure药品株式会社 | 含有多奈哌齐为有效成分的经皮吸收制剂 |
| WO2016209982A1 (en) | 2015-06-22 | 2016-12-29 | Corium International, Inc. | Transdermal adhesive composition comprising a poorly soluble therapeutic agent |
| KR102005201B1 (ko) | 2015-07-27 | 2019-07-29 | 히사미쓰 세이야꾸 가부시키가이샤 | 아세나핀 함유 첩부제의 제조 방법 |
| US10966936B2 (en) * | 2015-12-30 | 2021-04-06 | Corium, Inc. | Systems comprising a composite backing and methods for long term transdermal administration |
| CN105693556A (zh) | 2016-03-01 | 2016-06-22 | 巴斯特医药科技（常州）有限公司 | 卡巴拉汀酒石酸盐的转化方法及其产物制成的贴片 |
-
2017
- 2017-07-26 WO PCT/US2017/044047 patent/WO2018022814A1/en not_active Ceased
- 2017-07-26 KR KR1020197004938A patent/KR102424270B1/ko active Active
- 2017-07-26 EP EP17751886.7A patent/EP3490559A1/en not_active Withdrawn
- 2017-07-26 US US15/660,928 patent/US20180028461A1/en not_active Abandoned
- 2017-07-26 CN CN201780059413.9A patent/CN109789134A/zh active Pending
- 2017-07-26 JP JP2019503999A patent/JP7469879B2/ja active Active
- 2017-07-26 CA CA3031944A patent/CA3031944A1/en active Pending
- 2017-07-26 AU AU2017302305A patent/AU2017302305A1/en not_active Abandoned
- 2017-07-26 US US15/660,933 patent/US10016372B2/en active Active
-
2022
- 2022-02-22 JP JP2022025574A patent/JP2022060428A/ja active Pending
- 2022-11-28 US US18/070,319 patent/US20230086303A1/en not_active Abandoned
-
2023
- 2023-06-09 AU AU2023203613A patent/AU2023203613A1/en not_active Abandoned
-
2024
- 2024-01-05 JP JP2024000683A patent/JP2024019737A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019522024A5 (https=) | ||
| US20220395469A1 (en) | Transdermal drug delivery system for ketamine | |
| RU2314810C2 (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена | |
| JP6845162B2 (ja) | ケタミン経皮送達システム | |
| TWI244396B (en) | A composition for topical application of methylphenidate and a pharmaceutical composition for treating attention deficit disorder and attention deficit/hyperactivity disorder | |
| JP2022140751A (ja) | 塩薬物のｉｎ ｓｉｔｕでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法 | |
| TWI241911B (en) | Sustained release ranolazine formulations | |
| AU2008267058C1 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
| JP2023519959A5 (https=) | ||
| TWI302460B (en) | Pharmaceutical compositions and use thereof | |
| RU2007122410A (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda-рецептора, способ введения такого nmda-антагониста субъекту | |
| EP2550961A1 (en) | Solid preparation | |
| RU2015107517A (ru) | Фармацевтические композиции мемантина | |
| CA3127926A1 (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| JP2020536953A5 (https=) | ||
| US20120034276A1 (en) | Solid preparation | |
| WO2000064434A1 (en) | Percutaneous preparations containing oxybutynin | |
| JP2018500365A5 (https=) | ||
| US20210251906A1 (en) | Pregabalin extended-release formulations | |
| KR101697773B1 (ko) | 독소필린을 포함하는 변형 방출 조성물 | |
| JP2015526456A (ja) | アミノアルキルナイトラートの延長放出（Ｅｘｔｅｎｄｅｄｒｅｌｅａｓｅ）組成物 | |
| CA2438339A1 (en) | Use of buprenorphine for treatment of urinary incontinence | |
| TW201201806A (en) | Sustained release preparation | |
| JP2022540917A5 (https=) | ||
| WO2005032441A1 (en) | Transdermal delivery of oxybutynin in gel formulations |